Kiniksa Pharmaceuticals International, PLC Form 4 insider transactions

Kiniksa Pharmaceuticals CFO Mark Ragosa executed a pre-planned transaction, exercising stock options and simultaneously selling an equal number of Class A Ordinary Shares.

Kiniksa Pharmaceuticals' Chief Accounting Officer, Michael R. Megna, sold 17,000 Class A Ordinary Shares at a weighted average price of $32.35, following the exercise of options, as part of a pre-arranged 10b5-1 trading plan.

Kiniksa Pharmaceuticals Director Kimberly J. Popovits exercised stock options and subsequently sold a portion of her Class A Ordinary Shares.

Kiniksa Pharmaceuticals' Chief Operating Officer, Eben Tessari, exercised stock options and subsequently sold a portion of his Class A Ordinary Shares under a pre-arranged 10b5-1 trading plan.

Kiniksa Pharmaceuticals International, plc Director and 10% Owner Richard S. Levy reported the acquisition of 1,101 Class A Ordinary Shares on July 1, 2025, following the immediate vesting of Restricted Share Units.

Kiniksa Pharmaceuticals International, plc's Chief Operating Officer, Eben Tessari, engaged in pre-planned stock transactions, exercising options and selling a portion of Class A Ordinary Shares.

Barry D. Quart, a Director at Kiniksa Pharmaceuticals International, plc, executed a series of stock option exercises and subsequent sales of Class A Ordinary Shares over three days in June 2025.

Kiniksa Pharmaceuticals' Chief Operating Officer, Eben Tessari, executed a series of transactions involving the exercise of stock options and subsequent sale of 70,867 Class A Ordinary Shares, realizing significant gains under a pre-arranged 10b5-1 plan.

Kiniksa Pharmaceuticals International, plc Director G. Bradley Cole reported the acquisition of 16,798 share options and 2,799 Restricted Share Units, alongside the vesting and disposition of 3,173 Restricted Share Units, increasing his direct beneficial ownership of Class A Ordinary Shares to 12,546.

Key directors affiliated with Baker Bros. Advisors LP received substantial grants of Kiniksa Pharmaceuticals Class A Ordinary Shares and Non-Qualified Share Options, aligning their interests with the company's long-term performance.

Kiniksa Pharmaceuticals International, plc Director Richard S. Levy reported the acquisition of 3,173 Class A Ordinary Shares and the grant of new stock options and restricted share units, alongside the vesting of previously granted RSUs.

Kiniksa Pharmaceuticals International, plc Director and 10% Owner Thomas Malley reported the acquisition of new share options and restricted share units, alongside the vesting and conversion of existing RSUs into Class A Ordinary Shares.

Kiniksa Pharmaceuticals International, plc Director Tracey L. McCain reported the acquisition of new share options and restricted share units, alongside the disposition of previously vested restricted share units and corresponding Class A Ordinary Shares.

Kiniksa Pharmaceuticals International, plc Director Kimberly J. Popovits reported the acquisition of new stock options and restricted share units, alongside the vesting and conversion of previously held restricted share units into Class A Ordinary Shares.

Kiniksa Pharmaceuticals International, plc Director Barry D. Quart has reported the acquisition of 3,173 Class A Ordinary Shares through the vesting of Restricted Share Units, alongside new grants of 16,798 share options and 2,799 Restricted Share Units.

Kiniksa Pharmaceuticals' Chief Accounting Officer, Michael R. Megna, exercised stock options and subsequently sold an equal number of Class A Ordinary Shares on June 3, 2025, under a pre-arranged 10b5-1 trading plan.

Kiniksa Pharmaceuticals' Chief Commercial Officer, Ross Moat, exercised stock options and subsequently sold 27,594 Class A Ordinary Shares for a weighted average price of $29.02 per share, as part of a pre-arranged 10b5-1 trading plan.

Kiniksa Pharmaceuticals' Chief Financial Officer, Mark Ragosa, exercised stock options and subsequently sold 18,299 Class A Ordinary Shares for a gain, as disclosed in a recent SEC Form 4 filing.

Kiniksa Pharmaceuticals' Chairman and CEO, Sanj K Patel, exercised stock options and simultaneously sold a total of 86,270 Class A Ordinary Shares for proceeds exceeding $2.3 million, as part of a pre-arranged 10b5-1 trading plan.

Sanj K. Patel, Chairman and CEO of Kiniksa Pharmaceuticals International, plc, reports transactions involving Class A Ordinary Shares, including acquisitions and disposals, under a pre-arranged 10b5-1 trading plan.

Chief Operating Officer Tessari Eben reports the acquisition and disposal of Kiniksa Pharmaceuticals International, plc shares on May 19, 2025, under a pre-arranged 10b5-1 trading plan.

Kiniksa Pharmaceuticals' Chairman and CEO, Sanj K. Patel, reports transactions involving Class A Ordinary Shares, including acquisitions via option exercise and sales, under a pre-arranged 10b5-1 trading plan.

Chairman and CEO of Kiniksa Pharmaceuticals, Sanj K. Patel, executed a pre-arranged stock option plan, resulting in the acquisition and disposal of Class A Ordinary Shares.

John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals International, plc, reports the acquisition and disposal of Class A Ordinary Shares on May 7, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Michael R. Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals International, plc, reports multiple transactions involving Class A Ordinary Shares, including acquisitions and disposals, executed under a 10b5-1 plan.

Ross Moat, Chief Commercial Officer of Kiniksa Pharmaceuticals International, plc, reports the acquisition and disposal of Class A Ordinary Shares and Performance Share Units, including transactions made under a 10b5-1 plan.

Eben Tessari, Chief Operating Officer of Kiniksa Pharmaceuticals, received performance share units and options tied to the progress of KPL-387, a treatment for recurrent pericarditis.

Michael R. Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals International, plc, received performance share units and options tied to the progress of KPL-387, a treatment for recurrent pericarditis.

Mark Ragosa, CFO of Kiniksa Pharmaceuticals International, plc, received performance-based share units and options linked to the progress of KPL-387, a treatment for recurrent pericarditis.

Sanj K. Patel, CEO of Kiniksa Pharmaceuticals, receives performance share units and options tied to the progress of KPL-387, a treatment for recurrent pericarditis.